Journal of the American College of Cardiology
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
Trial in peopleInterventions
Papers by Amrut V. Ambardekar
2 results
- AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Trial in peopleInterventions